Latest Period
Q1 2026
Security Snapshot
Skye Bioscience, Inc. - Common Stock, par value $0.001 (SKYE) Institutional Ownership
CUSIP: 83086J200
13F Institutional Holders and Ownership History from Q4 2023 to Q1 2026
Institutions Reporting
36
Shares (Excl. Options)
16,129,917
Price
$0.61
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, par value $0.001
- Symbol
- SKYE on Nasdaq
- Shares outstanding
- 33,945,050
- Price per share
- $0.79
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 16,129,917
- Total reported value
- $9,913,850
- % of total 13F portfolios
- 0%
- Share change
- +8,305
- Value change
- -$26,926
- Number of holders
- 36
- Price from insider filings
- $0.79
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- SKYE - Skye Bioscience, Inc. - Common Stock, par value $0.001 is tracked under CUSIP 83086J200.
- 36 institutions reported positions in Q1 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 49 to 36 between Q4 2025 and Q1 2026.
- Reported value moved from $12,093,567 to $9,913,850.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 36 institutions filings for Q1 2026.
Security key
83086J200
Latest holder period
Q1 2026
13F holders
36
13D/G owners
3
CIK / CUSIP context first
Open Q1 2026 holders
SKYE full holder history
Skye Bioscience, Inc. SEC filings
Skye Bioscience, Inc. company facts
Skye Bioscience, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 83086J200:
Significant Owners of Skye Bioscience, Inc. - Common Stock, par value $0.001 (SKYE) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| 5AM Partners VII, LLC | 34% | -6.7% | $15,119,125 | -$203,807 | 11,541,317 | -1.3% | Andrew J. Schwab | 12 Dec 2025 |
| SPHERA FUNDS MANAGEMENT LTD. | 4.8% | $2,952,706 | 1,476,353 | Sphera Funds Management Ltd. | 31 Mar 2025 | |||
| Schonfeld Strategic Advisors LLC | 3.6% | -32% | $4,441,437 | -$1,996,997 | 1,115,939 | -31% | Schonfeld Strategic Advisors LLC | 30 Jun 2025 |
As of 31 Mar 2026, 36 institutional investors reported holding 16,129,917 shares of Skye Bioscience, Inc. - Common Stock, par value $0.001 (SKYE). This represents 48% of the company’s total 33,945,050 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Skye Bioscience, Inc. - Common Stock, par value $0.001 (SKYE) together control 48% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| 5AM Venture Management, LLC | 29% | 9,681,763 | 0% | 1.7% | $5,950,412 |
| Versant Venture Management, LLC | 5.9% | 2,007,704 | 0% | 0.87% | $1,233,935 |
| BAKER BROS. ADVISORS LP | 4.6% | 1,575,243 | +8.6% | 0.01% | $968,144 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.3% | 764,457 | 0% | 0% | $470,141 |
| SPHERA FUNDS MANAGEMENT LTD. | 2% | 678,928 | +42% | 0.07% | $417,269 |
| BlackRock, Inc. | 0.84% | 286,131 | +1.5% | 0% | $175,855 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.82% | 277,256 | +32% | 0% | $170,447 |
| MILLENNIUM MANAGEMENT LLC | 0.76% | 258,200 | -32% | 0% | $158,690 |
| PLATINUM INVESTMENT MANAGEMENT LTD | 0.69% | 233,095 | 0% | 0.04% | $143,260 |
| VANGUARD FIDUCIARY TRUST CO | 0.31% | 104,229 | 0% | 0% | $64,101 |
| STATE STREET CORP | 0.22% | 75,326 | 0% | 0% | $46,295 |
| UBS Group AG | 0.13% | 45,762 | +244% | 0% | $28,143 |
| XTX Topco Ltd | 0.12% | 40,919 | -23% | 0% | $25,149 |
| TWO SIGMA INVESTMENTS, LP | 0.08% | 25,684 | -50% | 0% | $15,785 |
| Engineers Gate Manager LP | 0.06% | 20,194 | -13% | 0% | $12,411 |
| NORTHERN TRUST CORP | 0.06% | 20,142 | 0% | 0% | $12,379 |
| BARCLAYS PLC | 0.05% | 18,089 | -15% | 0% | $11,117 |
| GROUP ONE TRADING LLC | 0.02% | 7,205 | -59% | 0% | $4,428 |
| Vanguard Global Advisers, LLC | 0.01% | 4,557 | 0% | 0% | $2,803 |
| MORGAN STANLEY | 0.01% | 2,549 | -40% | 0% | $1,567 |
| FEDERATED HERMES, INC. | 0% | 1,158 | 0% | 0% | $712 |
| OSAIC HOLDINGS, INC. | 0% | 600 | +29900% | 0% | $364 |
| NATIONAL BANK OF CANADA /FI/ | 0% | 400 | 0% | 0% | $242 |
| TD Waterhouse Canada Inc. | 0% | 79 | +216% | 0% | $51 |
| JPMORGAN CHASE & CO | 0% | 66 | 0% | 0% | $39 |
Institutional Holders of Skye Bioscience, Inc. - Common Stock, par value $0.001 (SKYE) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 16,129,917 | $9,913,850 | -$26,926 | $0.61 | 36 |
| 2025 Q4 | 16,131,666 | $12,093,567 | -$11,627,173 | $0.75 | 49 |
| 2025 Q3 | 19,883,163 | $78,141,353 | -$2,101,329 | $3.93 | 56 |
| 2025 Q2 | 20,399,360 | $85,269,369 | -$12,432,557 | $4.18 | 54 |
| 2025 Q1 | 24,700,100 | $39,307,441 | -$1,237,638 | $1.59 | 72 |
| 2024 Q4 | 25,208,315 | $71,310,457 | -$3,219,919 | $2.83 | 70 |
| 2024 Q3 | 25,729,728 | $100,585,169 | +$1,208,054 | $3.91 | 72 |
| 2024 Q2 | 24,496,645 | $196,252,371 | +$179,861,577 | $8.01 | 62 |
| 2024 Q1 | 2,009,303 | $31,404,827 | +$31,400,475 | $15.64 | 3 |
| 2023 Q4 | 1,600 | $4,352 | $2.72 | 1 |